A case of metastatic urachal cancer including a neuroendocrine component treated with gemcitabine, cisplatin and paclitaxel combination chemotherapy

Shin Ebara, Yasuyuki Kobayashi, Katsumi Sasaki, Motoo Araki, Morito Sugimoto, Koichiro Wada, Kei Fujio, Atsushi Takamoto, Toyohiko Watanabe, Hiroyuki Yanai, Yasutomo Nasu

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The present case report describes a case of recurrent and advanced urachal carcinoma including neuroendocrine features with iliac bone metastasis after partial cystectomy and adjuvant chemotherapy consisting of irinotecan and cisplatin in a 32-year-old man. He received gemcitabine/cisplatin/paclitaxel (GCP) combination chemotherapy, consisting of gemcitabin (1,000mg/m2) on day 1, 8, cisplatin (70mg/m2) on day 1, and paclitaxel (80mg/m2) on day 1 and 8. After three cycles of chemotherapy, PET-CT showed complete regression of the disease. So the patient underwent total cystourethrectomy, and histological examination showed an almost complete pathological response. External beam radiation therapy was also given to the ileac bone metastasis regions. However, PET-CT taken 17 months after the external beam radiation showed multiple lung metastases. He received GCP chemotherapy again, which resulted in a complete response again after three cycles of chemotherapy. This is the first report on GCP chemotherapy used not only as a salvage chemotherapy but also as a rechallenge regimen for metastatic urachal cancer including a neuroendocrine component.

Original languageEnglish
Pages (from-to)223-227
Number of pages5
JournalActa Medica Okayama
Volume70
Issue number3
Publication statusPublished - 2016

Keywords

  • Cisplatin
  • Gemcitabine
  • Neuroendocrine component
  • Paclitaxel
  • Urachal cancer

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'A case of metastatic urachal cancer including a neuroendocrine component treated with gemcitabine, cisplatin and paclitaxel combination chemotherapy'. Together they form a unique fingerprint.

  • Cite this